

SPL Biotech is a pharmaceutical and nutraceutical manufacturing company located in Puducherry, India. The company provides contract manufacturing services for brands across India and exports pharmaceutical and nutraceutical products to multiple international markets.
As part of its SME growth journey, SPL Biotech sought to assess export market potential, competitive positioning, and strategic pathways to scale export-led revenues.
CLIENT ENDORSEMENT
Expert perspectives and thought leadership on market intelligence, strategy consulting, and transformative business solutions
Strategy consulting objectives designed to provide actionable insights and sustainable competitive advantages
Evaluate the market potential for pharmaceutical and nutraceutical exports from India, with clear segmentation across domestic demand versus export-led opportunities.
Conduct competitor analysis to assess market positioning, export readiness, product alignment, and target geographies across key international markets.
Develop a structured strategy to scale revenues to ~INR 500 Cr (SOM) by FY30F through aligned export market entry, optimized product portfolio, and a strong partner ecosystem.
A systematic, research-driven approach designed to deliver actionable insights and sustainable outcomes.
Step 1
Conducted detailed sizing of the Total Addressable Market (TAM), Serviceable Available Market (SAM), and Serviceable Obtainable Market (SOM) for India’s domestic and export pharmaceutical and nutraceutical segments.
Step 2
Benchmarked competitors across export footprint, product platforms, pricing, regulatory registrations, and regional strategies to evaluate relative market positioning and scalability.
Step 3
Designed an export market-entry strategy for priority geographies, identified partner and distributor ecosystems, and defined an optimized product mix and contract manufacturing roadmap to support revenue scale-up.
The synthesis workshop produced a single prioritised action agenda. All three workstream recommendations were adopted into the client’s FY25 commercial plan within two weeks of delivery.
Identified a ₹936,000 Cr TAM for India’s pharmaceutical and nutraceutical sector.
Projected a ₹805,000 Cr SAM by FY30F, driven by export competitiveness and regulatory approvals.
Outlined a ₹500 Cr SOM by FY30F through focused export expansion and contract manufacturing.
Our research team can recommend the right approach for your specific business context.